Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth d...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2022-10, Vol.3 (10), p.100781, Article 100781
Main Authors: Fendler, Annika, Shepherd, Scott T C, Au, Lewis, Wu, Mary, Harvey, Ruth, Wilkinson, Katalin A, Schmitt, Andreas M, Tippu, Zayd, Shum, Benjamin, Farag, Sheima, Rogiers, Aljosja, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Barber, Taja, Emslie-Henry, Andrea, Caulfield-Lynch, Niamh, Byrne, Fiona, Deng, Daqi, Kjaer, Svend, Song, Ok-Ryul, Queval, Christophe J, Kavanagh, Caitlin, Wall, Emma C, Carr, Edward J, Caidan, Simon, Gavrielides, Mike, MacRae, James I, Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O'Flaherty, Molly, Shea, Robyn L, Gardner, Gail, Murray, Darren, Popat, Sanjay, Yousaf, Nadia, Jhanji, Shaman, Tatham, Kate, Cunningham, David, Van As, Nicholas, Young, Kate, Furness, Andrew J S, Pickering, Lisa, Beale, Rupert, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L V, Kassiotis, George, Howell, Michael, Nicholson, Emma, Walker, Susanna, Wilkinson, Robert J, Larkin, James, Turajlic, Samra
Format: Article
Language:English
Subjects:
Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
Clinical Studies as Topic
COVID-19 - prevention & control
COVID-19 Vaccines - immunology
Humans
Immunity
Neoplasms
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
ISSN:2666-3791
2666-3791
DOI:10.1016/j.xcrm.2022.100781